- Global regulatory submission for the antibody drug conjugate is based on the pivotal phase 2 DESTINY-Breast01 and phase 1 trials TOKYO, MUNICH and BASKING RIDGE, New Jersey, Sept. 9, 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results